Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudinenaive patients: A pilot study

Antiviral Therapy

Volumn 14, Issue 8, 2009, Pages 1081-1087

  Villa, Erica ^a   Lei, Barbara ^a   Taliani, Gloria ^b   Graziosi, Amalia ^a   Critelli, Rosina ^a   Luongo, Monica ^a   Gennari, William ^a   Bianchini, Marcello ^a   Ferretti, Ilva ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; LAMIVUDINE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GENETICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MIDDLE AGED; MUTATION; PHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 77949325618     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1465     Document Type: Article

References (22)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
2. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008; 40:603-617.
3. Lai CL, Chien R, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68. (Pubitemid 28304879)
4. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883-891. (Pubitemid 39288121)
5. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
6. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis. Gastroenterology 2003; 125:1714-1722. (Pubitemid 37500436)
7. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13:4085-4090.
8. Manolakopoulos S, Bethanis S, Elefsiniotis J, et al. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome. Aliment Pharmacol Ther 2006; 23:787-795. (Pubitemid 43344598)
9. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-182.
10. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
11. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19:670-675. (Pubitemid 38858201)
12. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
13. Jardi R, Buti M, Rodriguez-Frias F, et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999; 83:181-187. (Pubitemid 29528556)
14. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34:573-577. (Pubitemid 32786649)
15. Schiefke I, Klecker C, Maier M, et al. Sequential combination therapy of HBe antigen negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24:98-104. (Pubitemid 38584994)
16. Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-α and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100:2463-2471.
17. Marrone A, Zampino R, Portella G, et al. Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B. J Viral Hepat 2005; 12:186-191. (Pubitemid 40342177)
18. Niro GA, Fontana R, Gioffreda D, et al. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis 2007; 39:857-863. (Pubitemid 47215582)
19. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102:96-104. (Pubitemid 46072048)
20. Economou M, Manolakopoulos S, Trikalinos TA, et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005; 11:5882-5887. (Pubitemid 41662844)
21. Lok AS, McMahon BJ. Chronic Hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
22. Yim HJ, Hussain M, Liu Y, Wong SN, Fung S, Lok A. Evolution of multi-drug resistant hepatitis B virus during sequential therapy: implications on rescue therapy. Hepatology 2006; 44:703-712. (Pubitemid 44433727)